---
title: "Hansen Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 68.5384 million yuan, a decrease of 31.80%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254418220.md"
description: "Hansen Pharmaceutical released its semi-annual report for 2025, with operating revenue of 509 million yuan, a year-on-year increase of 5.91%. The net profit attributable to the parent company was 68.5384 million yuan, a year-on-year decrease of 31.80%; the net profit excluding non-recurring gains and losses was 64.7695 million yuan, a year-on-year decrease of 31.72%. The basic earnings per share were 0.1362 yuan"
datetime: "2025-08-25T10:44:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254418220.md)
  - [en](https://longbridge.com/en/news/254418220.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254418220.md)
generator: "portal-rs"
---

# Hansen Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 68.5384 million yuan, a decrease of 31.80%

According to the Zhitong Finance APP, Hansen Pharmaceutical (002412.SZ) released its semi-annual report for 2025, with operating revenue of 509 million yuan, a year-on-year increase of 5.91%. The net profit attributable to shareholders of the listed company was 68.5384 million yuan, a year-on-year decrease of 31.80%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 64.7695 million yuan, a year-on-year decrease of 31.72%. The basic earnings per share were 0.1362 yuan

### Related Stocks

- [002412.CN](https://longbridge.com/en/quote/002412.CN.md)

## Related News & Research

- [Alpha Entrepreneurial Partners Investment TGV takes 3.03% stake in q.beyond voting rights](https://longbridge.com/en/news/296450706.md)
- [23:31 ETWACO Corp. Unveils Redesigned 'ATLAS' Smart Public Water Refill Station Following Successful Tokyo PoC](https://longbridge.com/en/news/296430029.md)
- [Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program](https://longbridge.com/en/news/296389731.md)
- [Upside Gold exceeds 4,000-meter drill plan at Kena gold-copper project](https://longbridge.com/en/news/296356118.md)
- [Precision Peptide develops needle-free tirzepatide transdermal patch in U.S](https://longbridge.com/en/news/296344248.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**